Product Information
POTASSIUM CL ER 8 MEQ TABLET is a generic product labeled by Granules Pharmaceuticals Inc., priced at $0.1028 per EA under NDC 70010002101. Its NADAC has been published 282 times since May 12, 2021.
FDA first approved this application on Mar 4, 2020. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600 mg/1
Manufacturer
Granules Pharmaceuticals Inc.NDC
70010002101
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
POTASSIUM CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA211797FDA Approved
3/4/2020
TE Code
AB2
On Market Since
10/22/2020
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CL ER 8 MEQ TABLET has been published 282 times since May 12, 2021, and over the history we have for it it has declined 41.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1028 per EA |
|---|---|
| All-time high | $0.2037 (Jun 16, 2021) |
| All-time low | $0.1020 (Aug 19, 2026) |
| 52-week high | $0.1411 |
| 52-week low | $0.1020 |
| Median price | $0.1396 |
| Average price | $0.1445 |
| Largest weekly change | -39.3% (Apr 17, 2024) |
| Weeks tracked | 282 |
| Tracking since | May 12, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the POTASSIUM CHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Granules Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
POTASSIUM CHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CL ER 8 MEQ TABLET?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CL ER 8 MEQ TABLET, manufactured by Granules Pharmaceuticals Inc., is $0.1028 per EA (NDC 70010002101), effective Sep 30, 2026.
How has the price of POTASSIUM CL ER 8 MEQ TABLET changed over time?
Over the history we have for it, the NADAC for POTASSIUM CL ER 8 MEQ TABLET has declined 41.9%. It has been tracked across 282 weekly CMS publications since May 12, 2021.
What are the highest and lowest recorded NADAC prices for POTASSIUM CL ER 8 MEQ TABLET?
Since May 12, 2021, the NADAC for POTASSIUM CL ER 8 MEQ TABLET has ranged from a low of $0.1020 (Aug 19, 2026) to a high of $0.2037 (Jun 16, 2021), with a median of $0.1396 per EA.
Are there cheaper alternatives to POTASSIUM CL ER 8 MEQ TABLET?
No other NADAC-published product currently shares the active ingredient and strength of POTASSIUM CL ER 8 MEQ TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures POTASSIUM CL ER 8 MEQ TABLET?
POTASSIUM CL ER 8 MEQ TABLET (NDC 70010002101) is labeled by Granules Pharmaceuticals Inc., and CMS classifies it as a generic product.